| US 7,485,769 B2 | ||
| Transgenic mammals | ||
| Hiroshi Murakami, Tsukuba (Japan); Tatsuya Fujimura, Tsukuba (Japan); Yoichi Takahagi, Tsukuba (Japan); Koji Toyomura, Tsukuba (Japan); and Tamotsu Shigehisa, Tsukuba (Japan) | ||
| Assigned to Nippon Meat Packers, Inc., Osaka-shi (Japan) | ||
| Appl. No. 10/362,429 PCT Filed Aug. 27, 2001, PCT No. PCT/JP01/07331 § 371(c)(1), (2), (4) Date Feb. 25, 2003, PCT Pub. No. WO02/15681, PCT Pub. Date Feb. 28, 2002. |
||
| Claims priority of application No. 2000-256541 (JP), filed on Aug. 25, 2000. | ||
| Prior Publication US 2004/0073963 A1, Apr. 15, 2004 | ||
| Int. Cl. A01K 67/027 (2006.01); C12N 15/00 (2006.01) | ||
| U.S. Cl. 800—17 [800/14; 800/21; 800/22; 800/25] | 4 Claims |
| 1. A transgenic pig, whose genome comprises a transgene encoding human N-acetylglucosaminyltransferase (GnT III), for providing
organs for xenotransplantation comprising:
regulatory sequences capable of functioning in the hyperacute rejection-occurring local cells, wherein said regulatory sequences
are:
(A) a promoter of porcine complement inhibitor and the first intron of a human CD55 gene, or
(B) a cytomegalovirus (CMV) enhancer and chicken beta-actin promoter, and
said transgene encoding human N-acetylglucosaminyltransferase III (GnT III),
wherein said regulatory sequences are operably linked to said transgene encoding human GnT III, and
wherein said transgenic pig expresses GnT III in one or more organs selected from the group consisting of: heart, liver, lung,
kidney and spleen, and
wherein expression of GnT III decreases expression of galactose-α-1,3-galactose antigen in the one or more organs selected
from the group consisting of: heart, liver, lung, kidney and spleen, thereby decreasing hyperacute rejection in a human after
xenotransplantation of said one or more organs into a human.
|